Jazz Pharmaceuticals Inc reported that the final patient had completed participation in the first Phase III trial of their drug-in-development JZP-6 (sodium oxybate), for the treatment of fibromyalgia or chronic pain syndrome. 09-11-2008 | 11:59 hs.Author: Cate Kirby | Jazz Pharmaceuticals, based in Palo Alto, California, reported participation in their first Phase III trial with experimental JZP-6, for the treatment of fibromyalgia, has been completed, and it was on track to release study data in the fourth quarter. The first study for JZP-6 (sodium oxybate) enrolled 550 fibromyalgia patients at 65 centers in the U.S. A second late-stage study is enrolling patients at sites in the U.S. and Europe. Jazz CEO Samuel Saks said the company anticipated releasing primary efficacy and safety data from the first Phase III clinical trial on schedule in the fourth quarter of this year, and planned to submit an NDA to the Food and Drug Administration by the end of 2009. Sodium oxybate is also the active ingredient in Jazz´s drug Xyrem, being sold as a treatment for the sleep disorder narcolepsy.